Pros and cons of therapeutic drug monitoring of antiretroviral agents

Autor: P.W.H. Hugen, Rob E. Aarnoutse, David M. Burger

Publikováno v: Current Opinion in Infectious Diseases, 15, 17-22
Current Opinion in Infectious Diseases, 15, 1, pp. 17-22

Contains fulltext : 119505.pdf (Publisher’s version ) (Closed access) Therapeutic drug monitoring has the promise to become a part of routine patient care in the treatment of HIV infection. It is known that plasma drug concentrations of protease in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1451638463bbbf5d6a429696f78dbd3
https://doi.org/10.1097/00001432-200202000-00004

[Untitled]

Autor: J.W. Cohen Stuart, P.W.H. Hugen, R. Van Leusen, Yechiel A. Hekster, Peter P. Koopmans, David M. Burger, Frank P. Kroon

Publikováno v: Pharmacy World and Science. 24:83-86

Background: The soft-gel capsule (sgc) of saquinavir has been developed in order to improve the poor oral bioavailability of the original hard-gel capsules. However, in a Dutch study population using saquinavir-sgc plasma levels were lower than expec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3002fc670666d292535678ae1ecd8da6
https://doi.org/10.1023/a:1016121100568

A Retrospective, Cohort-Based Survey of Patients Using Twice-Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and Efficacy

Autor: Rob E. Aarnoutse, Jeanne P. Dieleman, David M. Burger, P.W.H. Hugen, Willem L. Blok, Jan M. Prins, Pieter L. Meenhorst, J. T. M. van der Meer, J. H. Ten Veen, Peter Reiss, J. W. Mulder, J. M. A. Lange, T. van der Poll

Publikováno v: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 26, 3, pp. 218--24
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 26, 218--24
Journal of acquired immune deficiency syndromes (1999), 26(3), 218-224. Lippincott Williams and Wilkins

Contains fulltext : 119509.pdf (Publisher’s version ) (Open Access) OBJECTIVE: To describe the pharmacokinetics, safety, and efficacy of twice-daily indinavir + ritonavir regimens DESIGN: A cohort-based survey of HIV-infected patients who either us

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0274f069017255a07240bef0ddbbcdad
https://doi.org/10.1097/00126334-200103010-00003

Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients

Autor: P.W.H. Hugen, Yechiel A. Hekster, C.P.W.G.M. Verwey-van Wissen, P.A. Baede-van Dijk, David M. Burger, Peter P. Koopmans

Publikováno v: Aids, 15, 991--8
Aids, 15, 8, pp. 991--8

Contains fulltext : 143520.pdf (Publisher’s version ) (Closed access) OBJECTIVE: To characterize sources of variation in plasma concentrations of nelfinavir and its active metabolite M8 and to evaluate the use of therapeutic drug monitoring for nel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24787d2f93f57a0ef7a189713fd362e9
https://doi.org/10.1097/00002030-200105250-00007

Low Plasma Concentrations of Indinavir are Related to Virological Treatment Failure in HIV-1-Infected Patients on Indinavir-Containing Triple Therapy

Autor: David M. Burger, Pieter L. Meenhorst, Monique Keuter, Kees Brinkman, Wil M. V. Dolmans, Jan Mulder, Peter P. Koopmans, P.W.H. Hugen, Richard M. W. Hoetelmans, Yechiel A. Hekster

Publikováno v: Antiviral Therapy. 3:215-220

All human immunodeficiency virus type 1 (HIV-1)-infected patients who started to use indinavir (800 mg three times a day) as part of their triple drug regimen were included in a study to determine the importance of low plasma concentrations of indina

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0450ab7b4a1e975364edbf80897acd33
https://doi.org/10.1177/135965359800300401